A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Clinical trial NCT01270464 · COMPLETED
Trial details
- NCT number
- NCT01270464
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-09-01
- Enrollment
- 315
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.